First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors

被引：2
|
作者：
Cooper, A. [1 ]
Andelkovic, V. [2 ]
Wilkinson, K. [1 ]
Ganju, V. [3 ]
Lundy, J. [3 ]
Hong, M. [1 ]
Airey, S. [2 ]
Meng, L. L. [4 ]
Shen, B. [5 ]
Li, H. [6 ]
Yao, L. [7 ]
Zhang, M. [3 ,8 ]
Coward, J. [2 ]
机构：
[1] Liverpool Hosp, Dept Med Oncol, South Western Sydney Local Hlth Dist, Liverpool, NSW, Australia
[2] ICON Canc Ctr South Brisbane, Dept Gynaeoncol, Brisbane, Qld, Australia
[3] Peninsula & Southeast Oncol, Dept Oncol, Frankston, Vic, Australia
[4] Abbisko Therapeut Co Ltd, Med Clin, Shanghai, Peoples R China
[5] Abbisko Therapeut Co Ltd, Translat Med, Shanghai, Peoples R China
[6] Abbisko Therapeut Co Ltd, Biometr, Shanghai, Peoples R China
[7] Abbisko Therapeut Co Ltd, Clin Pharmacol, Shanghai, Peoples R China
[8] Abbisko Therapeut Co Ltd, Clin Dev, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1886
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
700P
引用
收藏
页码：S487 / S487
页数：1
相关论文
共 50 条
  • [31] ORAL SMALL-MOLECULE LIVER-TROPIC PD-L1 INHIBITOR PHARMACOKINETICS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA
    Mondal, Arpita
    Thi, Emily P.
    Graves, Ingrid
    Heffernan, Gavin
    Xu, Fran
    Ozturk, Seyma
    Pohl, Amanda
    Fan, Kristi Y.
    Cole, Andrew
    Harasym, Troy
    Lam, Angela M.
    Sofia, Michael J.
    HEPATOLOGY, 2023, 78 : S1946 - S1947
  • [32] First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumors
    Guo, Ye
    Wang, Zishu
    Zhou, Huan
    Pan, Hongming
    Han, Weidong
    Deng, Yanhong
    Li, Qun
    Xue, Junli
    Ge, Xiaoxiao
    Wang, Shuang
    Wang, Jing
    Zhang, Yue
    Zhao, Congqiao
    Zhu, Huaqiang
    Wang, Yu
    Shen, Haige
    Liu, Dong
    Li, Jin
    BMC CANCER, 2024, 24 (01)
  • [33] Preliminary data from an ongoing phase 1 dose-escalation study of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors
    Tapia, Gonzalo
    Lundy, Joanne
    Richardson, Gary Edward
    Zhao, Niky
    Ebsworth, Karen
    Yue, Huibin
    Miao, Shichang
    Degoma, Emil
    Jain, Rita
    Schall, Thomas J.
    Sullivan, Kathleen
    Zhang, Penglie
    De Souza, Paul L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] First-in-human study of oral S 49076, a MET/AXL/FGFR inhibitor, in advanced solid tumors
    Postel-Vinay, S.
    Hollebecque, A.
    Soria, J. -C.
    Balandraud, S.
    Brendel, K.
    Cattan, V.
    Jacquet-Bescond, A.
    Busto, N. Lopez
    Malasse, S.
    Marfai, L.
    Pauly, J.
    Prudkin, L.
    Azaro, A.
    Rodon, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 37 - 37
  • [35] First-in-human dose escalation study of oral ONC201 in advanced solid tumors.
    Stein, Mark N.
    Mayer, Tina M.
    Moss, Rebecca Anne
    Silk, Ann W.
    Chan, Nancy
    Haffty, Bruce George
    DiPaola, Robert S.
    Beckett, Yasmeen
    Bentlyewski, Edward
    Zheng, Ling
    Fang, Bruno
    Allen, Joshua
    Mehnert, Janice M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
    Elena Elez
    Carlos Gomez-Roca
    Arturo Soto Matos-Pita
    Guillem Argiles
    Thibaud Valentin
    Cinthya Coronado
    Jorge Iglesias
    Teresa Macarulla
    Sarah Betrian
    Salvador Fudio
    Katrin Zaragoza
    Josep Tabernero
    Jean-Pierre Delord
    Investigational New Drugs, 2019, 37 : 674 - 683
  • [37] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
    Elez, Elena
    Gomez-Roca, Carlos
    Soto Matos-Pita, Arturo
    Argiles, Guillem
    Valentin, Thibaud
    Coronado, Cinthya
    Iglesias, Jorge
    Macarulla, Teresa
    Betrian, Sarah
    Fudio, Salvador
    Zaragoza, Katrin
    Tabernero, Josep
    Delord, Jean-Pierre
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 674 - 683
  • [38] A PHASE 1 STUDY EXPLORING THE SAFETY AND TOLERABILITY OF THE SMALL MOLECULE PD-L1 INHIBITOR, INCB086550, IN PATIENTS WITH SELECT ADVANCED TUMORS
    Le Tourneau, Christophe
    Piha-Paul, Sarina
    Prenen, Hans
    Delafontaine, Brant
    Pinato, David
    Santoro, Armando
    Kristeleit, Rebecca
    Spencer, Kristen
    Gangadhar, Tara
    Burris, Howard
    Kotecki, Nuria
    Basu, Bristi
    Graham, Donna
    Di Giacomo, Anna Maria
    Sahebjam, Solmaz
    Di Nicola, Massimo
    Gomez-Roca, Carlos
    Tomasini, Pascale
    Ascierto, Paolo
    Curigliano, Giuseppe
    Karasic, Thomas
    Geschwindt, Ryan
    Daniel, Jeannie
    Van Cutsem, Eric
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A805 - A805
  • [39] Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors
    Odegard, Jared M.
    Othman, Ahmed A.
    Lin, Kai-Wen
    Wang, Adele Y.
    Nazareno, Jonathan
    Yoon, Oh Kyu
    Ling, John
    Lad, Latesh
    Dunbar, P. Rod
    Thai, Dung
    Ang, Edmond
    Waldron, Nicholas
    Deva, Sanjeev
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (04)
  • [40] CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
    Naing, Aung
    Thistlethwaite, Fiona
    De Vries, Elisabeth G. E.
    Eskens, Ferry A. L. M.
    Uboha, Nataliya
    Ott, Patrick A.
    LoRusso, Patricia
    Garcia-Corbacho, Javier
    Boni, Valentina
    Bendell, Johanna
    Autio, Karen A.
    Randhawa, Manreet
    Durm, Greg
    Gil-Martin, Marta
    Stroh, Mark
    Hannah, Alison L.
    Arkenau, Hendrik-Tobias
    Spira, Alexander
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (07)
12345